Greenberg Karen, Ross Jennifer A, Kurtz Thomas A, Deans Abby E, Veznedaroglu Erol, Liebman Kenneth, Hakma Zakaria, Rahme Rudy, Binning Mandy
Neurosciences, Global Neurosciences Institute, Pennington, USA.
Radiology, Main Line Health, Bryn Mawr, USA.
Cureus. 2025 Aug 14;17(8):e90098. doi: 10.7759/cureus.90098. eCollection 2025 Aug.
Hypersensitivity reactions to iodinated contrast pose a challenge when urgent neuroimaging is needed in acute stroke. Limited protocols exist for high-risk patients in emergent settings.
To evaluate the safety and efficacy of an emergent intravenous (IV) dye preparation protocol for stroke-alert patients with known contrast allergies, enabling timely neuroimaging.
This retrospective study reviewed stroke-alert patients from 2021 to 2023 at a comprehensive stroke center. Patients with documented IV dye allergies but no history of airway edema or anaphylaxis were included. An emergent IV dye preparation protocol was administered, consisting of diphenhydramine 50 mg IV, famotidine 20 mg IV, and dexamethasone 10 mg IV before contrast CT angiography (CTA) or CT perfusion (CTP). Data analysis included descriptive statistics, and statistical significance was determined using chi-square tests, with a -value threshold of 0.05.
Of 1,001 stroke-alert patients, 58 (5.8%) had a contrast allergy. Twenty-five of these (43%) received emergent contrast imaging; 16 (64%) were female, with a mean age of 66 ± 15 years. Six of 25 (24%) had a large vessel occlusion or severe carotid stenosis detected by CTA/CTP, compared to two of 26 (7.7%) in the non-contrast group (attributable risk 0.16; 95% confidence interval (CI) -0.07 to 0.39; = 0.11). No adverse reactions occurred within 24 hours post-imaging. The number needed to treat was six.
The emergent IV dye preparation protocol was safe, enabled timely imaging, and improved detection of treatable large-vessel occlusions in acute stroke patients with contrast allergies.
当急性卒中患者需要紧急进行神经影像学检查时,对碘化造影剂的超敏反应是一个挑战。在紧急情况下,针对高危患者的方案有限。
评估一种针对已知造影剂过敏的卒中预警患者的紧急静脉注射染料制备方案的安全性和有效性,以实现及时的神经影像学检查。
这项回顾性研究对2021年至2023年在一家综合卒中中心的卒中预警患者进行了评估。纳入有静脉注射染料过敏记录但无气道水肿或过敏反应病史的患者。在进行对比增强CT血管造影(CTA)或CT灌注(CTP)之前,实施了一种紧急静脉注射染料制备方案,包括静脉注射50毫克苯海拉明、20毫克法莫替丁和10毫克地塞米松。数据分析包括描述性统计,并使用卡方检验确定统计学意义,P值阈值为0.05。
在1001例卒中预警患者中,58例(5.8%)有造影剂过敏。其中25例(43%)接受了紧急对比成像;16例(64%)为女性,平均年龄为66±15岁。25例中有6例(24%)通过CTA/CTP检测到有大血管闭塞或严重颈动脉狭窄,而非对比组的26例中有2例(7.7%)(归因风险0.16;95%置信区间(CI)-0.07至0.39;P=0.11)。成像后24小时内未发生不良反应。治疗所需人数为6。
紧急静脉注射染料制备方案是安全的,能够实现及时成像,并提高了对有造影剂过敏的急性卒中患者可治疗的大血管闭塞的检测率。